$0.57
9.03% yesterday
Nasdaq, Nov 15, 09:49 pm CET
ISIN
US0977021049
Symbol
BOLT
Sector
Industry

Bolt Biotherapeutics Inc Stock price

$0.57
-0.06 10.24% 1M
-0.26 31.87% 6M
-0.55 49.51% YTD
-0.41 42.30% 1Y
-9.39 94.32% 3Y
-31.58 98.24% 5Y
-31.58 98.24% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.06 9.14%
ISIN
US0977021049
Symbol
BOLT
Sector
Industry

Key metrics

Market capitalization $21.64m
Enterprise Value $-14.77m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.24
EV/Sales (TTM) EV/Sales -1.51
P/S ratio (TTM) P/S ratio 2.21
P/B ratio (TTM) P/B ratio 0.30
Revenue growth (TTM) Revenue growth 35.86%
Revenue (TTM) Revenue $9.78m
EBIT (operating result TTM) EBIT $-72.33m
Free Cash Flow (TTM) Free Cash Flow $-61.17m
Cash position $54.59m
EPS (TTM) EPS $-1.71
P/E forward negative
P/S forward 2.71
EV/Sales forward negative
Short interest 0.22%
Show more

Is Bolt Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Bolt Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Bolt Biotherapeutics Inc forecast:

4x Hold
100%

Analyst Opinions

4 Analysts have issued a Bolt Biotherapeutics Inc forecast:

Hold
100%

Financial data from Bolt Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
9.78 9.78
36% 36%
100%
- Direct Costs 1.85 1.85
54% 54%
19%
7.93 7.93
149% 149%
81%
- Selling and Administrative Expenses 18 18
2% 2%
186%
- Research and Development Expense 60 60
4% 4%
616%
-70 -70
4% 4%
-721%
- Depreciation and Amortization 1.85 1.85
54% 54%
19%
EBIT (Operating Income) EBIT -72 -72
7% 7%
-740%
Net Profit -65 -65
9% 9%
-666%

In millions USD.

Don't miss a Thing! We will send you all news about Bolt Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bolt Biotherapeutics Inc Stock News

Neutral
GlobeNewsWire
8 days ago
BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from BDC-1001 data suggest Boltbody™  ISACs with enhanced immune activation could offer greater efficacy, warranting further testing REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics...
Neutral
GlobeNewsWire
2 months ago
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appoint...
Neutral
Business Wire
2 months ago
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024. Bolt describes itself as a “clinical-stage biopharmaceutical company, [that] engages in the development of immunotherapies for the ...
More Bolt Biotherapeutics Inc News

Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Head office United States
CEO William Quinn
Employees 100
Founded 2015
Website www.boltbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today